RNS Number:7425N
VASTox plc
20 June 2005


For Immediate Release                                               20 June 2005


                                   VASTox plc

                          ("VASTox" or "the Company")


                               Two new agreements

Oxford, UK: (20 June) 2005 - VASTox plc (AIM: VOX), the Oxford-based drug
discovery and services business, is pleased to announce today that it has signed
two new agreements in the field of drug development services and chemical
genomics.

The service contract is with a leading UK-based biopharmaceutical company to
provide chemistry synthesis and process development expertise to help accelerate
their drug development programmes.  VASTox have committed four full-time
employees to this project for the first twelve months. Terms of the contract
were undisclosed.

The chemical genomics collaboration has been signed with an unnamed top-tier
global agrochemical company to conduct a pilot study to understand the affect of
particular pesticides on the genome of the fruitfly (Drosophila melanogaster).
The partner recognises both the value of fruitflies in identifying gene targets
and the world-leading expertise of VASTox in this area.  The financial terms
were undisclosed.

Dr Steven Lee, CEO of VASTox, said: "These contracts demonstrate the growing
recognition by our industry partners of our technology platforms.  In using our
chemical genomics approach, the principle of identifying targets for
agrochemicals is equally applicable to identifying targets for human diseases
and VASTox retains all rights to developed technology for pharmaceuticals."


For more information please contact:


VASTox plc
Steven Lee, Chief Executive Officer                                07766 913 898

Buchanan Communications
Tim Anderson / Mark Court / Mary-Jane Johnson                      020 7466 5000


Notes for Editors:

About VASTox

VASTox is a chemical genomics technology company that both provides services to
the pharmaceutical industry, and discovers and develops proprietary novel drugs.
The company's technology platform aims to use high volume, high content
screening using zebrafish and fruitflies to provide a high level of
predictability of the efficacy and toxicity of potential drug compounds in
humans which has the potential to dramatically decrease the time and cost of
drug discovery and development. VASTox was formed in January 2003, from the
University of Oxford, by some of the UK's foremost scientists who have taken a
highly creative approach to the problems involved in drug discovery and who have
a proven record in delivering technological excellence. The company listed on
the London Stock Exchange AIM in October 2004.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRGUUPPQUPAGQM
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vox Valor Capital Charts.
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vox Valor Capital Charts.